Double Bond Pharmaceuticals Eurostar project Belopenem will start already October 1, 2018 instead of previously announced November 1, 2018. The project is a collaboration with, amongst others, Karolinska Institutet and SME from France, where Double Bond Pharmaceutical will act as leader as the project’s largest participant.
“We are eager to develop the BeloGal® platform for new products and are therefore very pleased that we can start work earlier than planned”, commented Igor Lokot, CEO of Double Bond Pharmaceutical.
More about the Belopenem project
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 4 of September 2018.
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Stock short name:
Share ISIN code:
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.